Global AI-driven Peptide Drug Discovery Platform Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global AI-driven Peptide Drug Discovery Platform market size will reach US$ 1320 million by 2031.
AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.
The global AI-driven peptide drug R&D market is in a period of rapid growth, with the core driving force coming from the high failure rate of traditional peptide R&D (over 90% elimination rate in the preclinical stage) and the significant advantages of AI technology in reducing costs and increasing efficiency (shortening the early R&D cycle by 50%). North America occupies a dominant position (about 48% market share in 2023), mainly due to the concentration of leading companies such as Insilico Medicine and Schrödinger and active biopharmaceutical venture capital; the Asia-Pacific region has the fastest growth rate (CAGR of 29%), thanks to China's "14th Five-Year Plan for Bioeconomic Development" policy support for AI pharmaceuticals and technological breakthroughs by local companies such as Tai Technology. In the sub-sectors, tumor treatment (PDC drug development) and anti-infective drugs (antimicrobial peptide optimization) account for more than 60% of the market share, while metabolic diseases and neurological diseases have become emerging growth poles due to breakthroughs in GLP-1 analogs and blood-brain barrier penetration technology. The challenges faced by the industry are the low clinical conversion rate (only 7% of AI-designed drug candidates enter Phase II clinical trials) and data barriers (data closure of pharmaceutical companies limits model training), but the deepening cooperation between multinational pharmaceutical companies and AI platforms (such as Pfizer and Cyclica jointly developing peptide vaccines) is promoting the openness of the ecosystem. In the future, peptide-nucleic acid conjugates (PepRNA) and AI-driven fully automated laboratories (such as the Strateos cloud-based robotics platform) may reshape the industry's competitive landscape.
LPI (LP Information)' newest research report, the “AI-driven Peptide Drug Discovery Platform Industry Forecast” looks at past sales and reviews total world AI-driven Peptide Drug Discovery Platform sales in 2024, providing a comprehensive analysis by region and market sector of projected AI-driven Peptide Drug Discovery Platform sales for 2025 through 2031. With AI-driven Peptide Drug Discovery Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI-driven Peptide Drug Discovery Platform industry.
This Insight Report provides a comprehensive analysis of the global AI-driven Peptide Drug Discovery Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AI-driven Peptide Drug Discovery Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AI-driven Peptide Drug Discovery Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AI-driven Peptide Drug Discovery Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AI-driven Peptide Drug Discovery Platform.
This report presents a comprehensive overview, market shares, and growth opportunities of AI-driven Peptide Drug Discovery Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
Design and Generation Platform
Screening and Optimization Platform
Data-driven Platform
Others
Segmentation by Application:
Scientific Research
Pharmaceuticals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Creative Peptides
Exscalate
Generate Biomedicines
Receptor.AI
Insilico Medicine
Schrödinger
BenevolentAI
Evotec
PeptiFinder
Xtalpi
Sun Novo
Zonsen Peplib Biotech
Tide Tron Biotech
Please note: The report will take approximately 2 business days to prepare and deliver.
AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.
The global AI-driven peptide drug R&D market is in a period of rapid growth, with the core driving force coming from the high failure rate of traditional peptide R&D (over 90% elimination rate in the preclinical stage) and the significant advantages of AI technology in reducing costs and increasing efficiency (shortening the early R&D cycle by 50%). North America occupies a dominant position (about 48% market share in 2023), mainly due to the concentration of leading companies such as Insilico Medicine and Schrödinger and active biopharmaceutical venture capital; the Asia-Pacific region has the fastest growth rate (CAGR of 29%), thanks to China's "14th Five-Year Plan for Bioeconomic Development" policy support for AI pharmaceuticals and technological breakthroughs by local companies such as Tai Technology. In the sub-sectors, tumor treatment (PDC drug development) and anti-infective drugs (antimicrobial peptide optimization) account for more than 60% of the market share, while metabolic diseases and neurological diseases have become emerging growth poles due to breakthroughs in GLP-1 analogs and blood-brain barrier penetration technology. The challenges faced by the industry are the low clinical conversion rate (only 7% of AI-designed drug candidates enter Phase II clinical trials) and data barriers (data closure of pharmaceutical companies limits model training), but the deepening cooperation between multinational pharmaceutical companies and AI platforms (such as Pfizer and Cyclica jointly developing peptide vaccines) is promoting the openness of the ecosystem. In the future, peptide-nucleic acid conjugates (PepRNA) and AI-driven fully automated laboratories (such as the Strateos cloud-based robotics platform) may reshape the industry's competitive landscape.
LPI (LP Information)' newest research report, the “AI-driven Peptide Drug Discovery Platform Industry Forecast” looks at past sales and reviews total world AI-driven Peptide Drug Discovery Platform sales in 2024, providing a comprehensive analysis by region and market sector of projected AI-driven Peptide Drug Discovery Platform sales for 2025 through 2031. With AI-driven Peptide Drug Discovery Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI-driven Peptide Drug Discovery Platform industry.
This Insight Report provides a comprehensive analysis of the global AI-driven Peptide Drug Discovery Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AI-driven Peptide Drug Discovery Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AI-driven Peptide Drug Discovery Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AI-driven Peptide Drug Discovery Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AI-driven Peptide Drug Discovery Platform.
This report presents a comprehensive overview, market shares, and growth opportunities of AI-driven Peptide Drug Discovery Platform market by product type, application, key players and key regions and countries.
Segmentation by Type:
Design and Generation Platform
Screening and Optimization Platform
Data-driven Platform
Others
Segmentation by Application:
Scientific Research
Pharmaceuticals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Creative Peptides
Exscalate
Generate Biomedicines
Receptor.AI
Insilico Medicine
Schrödinger
BenevolentAI
Evotec
PeptiFinder
Xtalpi
Sun Novo
Zonsen Peplib Biotech
Tide Tron Biotech
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
130 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Long-lasting Pet Deworming Products by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Long-lasting Pet Deworming Products by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
